Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
FLOT
Gastric cancer
Gastro-esophageal junction adenocarcinoma
Microsatellite instability status
Perioperative chemotherapy
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
10
12
2022
accepted:
04
02
2023
medline:
24
7
2023
pubmed:
17
2
2023
entrez:
16
2
2023
Statut:
ppublish
Résumé
FLOT regimen is the standard perioperative treatment in Western countries for patients with locally advanced gastric (GC) or gastroesophageal junction cancer (GEJC). High microsatellite instability (MSI-H) and Mismatch Repair deficient (dMMR) demonstrated a favorable prognostic role and a concomitant negative predictive impact on the benefit of perioperative 5-fluorouracil-based doublets; however, its role in pts receiving FLOT chemotherapy is still unclear. This is a retrospective, multicenter observational study of 265 pts with GC/GEJC treated with perioperative FLOT regimen in 11 Italian oncology centers between January 2017 to December 2021 and analyzed for microsatellite status. The MSI-H phenotype was found in 27 (10.2%) of 265 analyzed tumors. Compared to microsatellite stable (MSS) and Mismatch Repair proficient (pMMR) cases, MSI-H/dMMR were more frequently female (48.1% vs. 27.3%, p = 0.0424), elderly pts (age > 70 years, 44.4% vs. 13.4%, p = 0.0003), Laurens's intestinal type (62.5% vs. 36.1%, p = 0.02) and pts with a primary location tumor in the antrum (37 vs. 14.3%, p = 0.0004). A statistically significant difference in the rate of pathologically negative lymph node emerged (63% vs 30.7%, p = 0.0018). Compared to the MSS/pMMR tumor population, the MSI-H/dMMR subgroup had a better DFS (median not reached [NR] vs. 19.5 [15.59-23.59] mos, p = 0.031) and OS (median NR vs. 34.84 [26.68-47.60] mos, p = 0.0316). These real-world data confirm that FLOT treatment is effective in daily clinical practice for locally advanced GC/GEJC, also in the MSI-H/dMMR subgroup. It also showed a higher rate of nodal status downstaging and a better outcome of MSI-H/dMMR pts in comparison to MSS/pMMR.
Sections du résumé
BACKGROUND
BACKGROUND
FLOT regimen is the standard perioperative treatment in Western countries for patients with locally advanced gastric (GC) or gastroesophageal junction cancer (GEJC). High microsatellite instability (MSI-H) and Mismatch Repair deficient (dMMR) demonstrated a favorable prognostic role and a concomitant negative predictive impact on the benefit of perioperative 5-fluorouracil-based doublets; however, its role in pts receiving FLOT chemotherapy is still unclear.
METHODS
METHODS
This is a retrospective, multicenter observational study of 265 pts with GC/GEJC treated with perioperative FLOT regimen in 11 Italian oncology centers between January 2017 to December 2021 and analyzed for microsatellite status.
RESULTS
RESULTS
The MSI-H phenotype was found in 27 (10.2%) of 265 analyzed tumors. Compared to microsatellite stable (MSS) and Mismatch Repair proficient (pMMR) cases, MSI-H/dMMR were more frequently female (48.1% vs. 27.3%, p = 0.0424), elderly pts (age > 70 years, 44.4% vs. 13.4%, p = 0.0003), Laurens's intestinal type (62.5% vs. 36.1%, p = 0.02) and pts with a primary location tumor in the antrum (37 vs. 14.3%, p = 0.0004). A statistically significant difference in the rate of pathologically negative lymph node emerged (63% vs 30.7%, p = 0.0018). Compared to the MSS/pMMR tumor population, the MSI-H/dMMR subgroup had a better DFS (median not reached [NR] vs. 19.5 [15.59-23.59] mos, p = 0.031) and OS (median NR vs. 34.84 [26.68-47.60] mos, p = 0.0316).
CONCLUSIONS
CONCLUSIONS
These real-world data confirm that FLOT treatment is effective in daily clinical practice for locally advanced GC/GEJC, also in the MSI-H/dMMR subgroup. It also showed a higher rate of nodal status downstaging and a better outcome of MSI-H/dMMR pts in comparison to MSS/pMMR.
Identifiants
pubmed: 36795195
doi: 10.1007/s00432-023-04636-y
pii: 10.1007/s00432-023-04636-y
pmc: PMC10356632
doi:
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6601-6611Informations de copyright
© 2023. The Author(s).
Références
Eur J Surg Oncol. 2016 Jan;42(1):18-27
pubmed: 26632080
J Clin Oncol. 2023 Jan 10;41(2):255-265
pubmed: 35969830
Br J Surg. 2018 Feb;105(3):159-167
pubmed: 29091259
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
JAMA Oncol. 2017 Sep 01;3(9):1197-1203
pubmed: 28241187
Cancers (Basel). 2021 Jun 07;13(11):
pubmed: 34200267
Ann Oncol. 2022 Oct;33(10):1005-1020
pubmed: 35914639
Int J Cancer. 2019 Apr 1;144(7):1697-1703
pubmed: 30499151
Ann Surg. 2019 Aug;270(2):309-316
pubmed: 29727332
Dig Liver Dis. 2023 Jan;55(1):123-130
pubmed: 35397988
Ann Surg Oncol. 2016 Mar;23(3):943-50
pubmed: 26530444
J Clin Oncol. 2019 Dec 10;37(35):3392-3400
pubmed: 31513484
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2016 Aug 10;34(23):2721-7
pubmed: 27298411
Int J Cancer. 2012 Jul 15;131(2):505-11
pubmed: 21898388
Best Pract Res Clin Gastroenterol. 2021 Mar-Apr;50-51:101738
pubmed: 33975679
J Pathol Clin Res. 2019 Oct;5(4):227-239
pubmed: 31206244
Gastric Cancer. 2017 Jan;20(1):156-163
pubmed: 26796888
Transl Gastroenterol Hepatol. 2019 Aug 20;4:59
pubmed: 31559340
Dig Liver Dis. 2022 Oct;54(10):1335-1341
pubmed: 35907691
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101691
pubmed: 33852952
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
Chin J Cancer Res. 2021 Jun 30;33(3):331-342
pubmed: 34321830
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686